Lung Cancer News Update

The Lung Cancer Foundation of America Launches a New Initiative to Help Hairdressers Provide Potentially Life-Saving Information About Lung Cancer to The Black Community “Los Angeles, CA, Dec. 20, 2022 (GLOBE NEWSWIRE) — Lung cancer is a leading cause of death for Black men and women, and research shows that hairdressers are some of the most trusted people in the African American community. The Lung Cancer Foundation of America is producing an easy-to-follow training video for hairdressers, so they help relay critical information about lung cancer to the black community. Hairdressers often ask: “How are the kids?” or, How’s your hair?” But through a targeted training program with the LCFA, if a client is diagnosed with lung cancer, hairdressers could soon be asking: “What’s your biomarker?” Gilead-Arcus Partnered Domvanalimab Combo Study Show Improved Progression-Free Survival In Lung Cancer Patients “Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NASDAQ: RCUS) announced results from the fourth interim analysis of the ARC-7 Phase 2 study for metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase mutations.” S2302 Pragmatica-Lung Trial: Reaching more representative groups of patients with exciting clinical trials “S2302 Pragmatica-Lung is a federally-funded, streamlined clinical trial examining a new combination of agents in patients with advanced non-small cell lung cancer (NSCLC). Like most studies, it is focused on improving outcomes for patients with cancer—but it is also poised to simplify and transform the entire clinical trials model as we know it.” In-House Next-Generation Sequencing Improves Turnaround Time in NSCLC “Next-generation sequencing (NGS) offers key benefits as more biomarkers emerge in the non–small cell lung cancer (NSCLC) space as it can assist in determining the best treatment options for patients.” New Bacterial Therapy Approach to Treat Lung Cancer “Newswise — New York, NY—December 23, 2022—Lung cancer is the deadliest cancer in the United States and around the world. Many of the currently available therapies have been ineffective, leaving patients with very few options. A promising new strategy to treat cancer has been bacterial therapy, but while this treatment modality has quickly progressed from laboratory experiments to clinical trials in the last five years, the most effective treatment for certain types of cancers may be in combination with other drugs.” ACCC Releases New Oncology Practice Transformation and Integration Center (OPTIC) Resource Library “The Association of Community Cancer Centers (ACCC) is announcing the release of a new tool intended to facilitate education and adoption of new clinical and technological advancements in diagnosis, staging, and treatment of cancer. Referred to as the OPTIC Resource Library, this tool offers resources for the multidisciplinary care team to use to support adoption of innovations, emerging practices, or establishing guidelines in oncology across disciplines.” Study Suggests AI can Predict Risk of Lung Cancer Returning Using CT Scans “December 26, 2022 — Artificial intelligence (AI) could help identify the risk of cancer returning in non-small cell lung cancer (NSCLC) patients using CT scans, according to the latest results from a study led by researchers from The Royal Marsden NHS Foundation Trust in collaboration with The Institute of Cancer Research, London, and Imperial College London.” Video: Importance of Biomarker Testing in Patients with NSCLC “Two experts discuss the evolving treatment landscape for patients with non-small cell lung cancer (NSCLC) and reviews the role of molecular testing and discusses some of the challenges faced.” Experts on the Use of ADCs in HER2-Mutated NSCLC Treatment “Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss the use of antibody-drug conjugates (ADCs) in HER2-mutated non–small cell lung cancer.”